Close

Anti-DLBCL T cell receptor (alpha6 beta13), pCDTCR1 (TCR-C039Z)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-DLBCL T cell receptor (TCR) is constructed for the engineering of T cell to target Human DLBCL. The T cells are genetically modified through transduction with a lentiviral vector expressing DLBCL-specific T cell receptor. And the vector product was designed for the treatment of Lymphoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • DLBCL
  • Target Species
  • Human
  • Format
  • Non-modified
  • Allele
  • HLA-A2
  • Targeting Diseases
  • Lymphoma
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • TCR Clone
  • alpha6 beta13
  • Host Species
  • Human

Target

  • Official Symbol
  • DLBCL
  • Introduction
  • Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumor which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms—fever, weight loss, and night sweats.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-DLBCL T cell receptor (alpha6 beta13), pCDTCR1 (TCR-C039Z). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.